Result: Risk Minimisation Materials for medicines starting with the letter O

Olumiant

Eli Lilly and Company Limited

Olumiant 2 mg and 4 mg Film-Coated Tablets guidance for Healthcare Professionals

Important Risk Minimization information for healthcare professionals prescribing Olumiant.

For Healthcare Professionals

Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card

Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card containing important safety information for patients.

Onpattro

Alnylam UK Ltd

Onpattro (patisiran) Educational Material for Healthcare Professionals

Educational Material for Healthcare Professionals to ensure safe use of Onpattro in the home setting.

For Healthcare Professionals

Onpattro (patisiran) Educational Material for Patients

Educational Material for patients for safe use of Onpattro in the home.

OPDIVO

Bristol-Myers Squibb Pharmaceuticals limited

Opdivo (nivolumab) Important Risk Minimisation Information for Healthcare Professionals

This risk minimisation material is a condition of the marketing authorisation. Please ensure you are familiar with this document before prescribing nivolumab, or nivolumab in combination with ipilimumab, as it contains important safety information. In particular, it is aimed at increasing awareness of immune-related adverse reactions (irARs) with nivolumab monotherapy, or when nivolumab is used in combination with ipilimumab. It also provides information on treatment modifications for irARs, e.g. when to withhold or permanently discontinue treatment. This material was last updated in Apr-2019: Update to the information on managing Grade 3 diarrhoea/colitis in the "Early Diagnosis and Appropriate Management" and “Immune-Related Adverse Reactions and Treatment Modifications” sections. Treatment must also be permanently discontinued if Grade 3 diarrhoea or colitis occurs during the second phase of treatment with nivolumab monotherapy following combination therapy.

For Healthcare Professionals

Opdivo (nivolumab) Patient Alert Card

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab. This educational material was UPDATED in Nov-2018. Changes to the material include an instruction for patients to tell their doctor before they start receiving nivolumab if they have received a bone marrow or stem cell transplant from another person (allogeneic)

Opsumit

Janssen-Cilag Ltd

Opsumit HCP Brochure

These frequently asked questions (FAQs) are provided by Actelion Pharmaceuticals for prescribers and other healthcare professionals (HCPs) who are involved in the treatment of patients on OPSUMIT for whom you have determined are capable of complying with the requirements for the safe use of OPSUMIT.

For Healthcare Professionals

Opsumit Patient Alert Card

It is important that you report immediately to your prescribing doctor any pregnancy or side effects that may occur during treatment with Opsumit.

For Healthcare Professionals

prescribers Checklist

For Healthcare Professionals

Ozurdex

Allergan Ltd

Ozurdex - Patient Guide

A patient guide to OZURDEX therapy